3-V Bioscience-2640
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metabolic Syndrome
Conditions
Metabolic Syndrome
Trial Timeline
Feb 1, 2017 → Jan 30, 2019
NCT ID
NCT02948569About 3-V Bioscience-2640
3-V Bioscience-2640 is a phase 1/2 stage product being developed by Sagimet Biosciences for Metabolic Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02948569. Target conditions include Metabolic Syndrome.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02948569 | Phase 1/2 | Completed |
Competing Products
20 competing products in Metabolic Syndrome